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Abstract
Background: Current first-line anti-proteinuric treatments for nephrotic syndrome (NS) do not produce an effective
response in all patients and are not tolerated by some patients. Additional effective and tolerable treatment
options in NS are strongly needed. This retrospective case series is the largest to date to examine Acthar gel
(adrenocorticotropic hormone, ACTH) in patients with varied-etiology NS.
Methods: This multicenter retrospective case series included adult patients with NS (N = 44) treated with
Acthar gel at 6 clinical practices. NS etiologies included idiopathic focal segmental glomerulosclerosis (FSGS,
15), idiopathic membranous nephropathy (iMN, 11), IgA nephropathy (IgAN, 5), diabetic nephropathy (DN, 4),
systemic lupus erythematosus class V membranous lupus nephritis (MLN, 2), minimal change disease (MCD, 2),
membranoproliferative glomerulonephritis (MPGN, 1), fibrillary glomerulonephritis (FGN, 1), and unbiopsied NS
(3). Proteinuria response was assessed as percent reduction from baseline and percent of patients meeting
complete remission (final proteinuria <500 mg/d), partial remission (≥50 % reduction in proteinuria from
baseline and final proteinuria 500–3500 mg/d), clinical response (≥30 % reduction in proteinuria from baseline
that did not meet criteria for complete or partial remission), and no response (failed to meet remission or
clinical response criteria) following Acthar gel therapy. Safety and tolerability were examined using adverse
event (AE) frequency reported by patients or treating nephrologists and frequency of early discontinuation
of treatment due to AEs.
Results: 68.2 % (30/44) of patients had received prior NS treatment with immunosuppressive or cytotoxic
therapies. Thirty-seven patients completed Acthar gel treatment. Seven patients (15.9 %) had early termination
due to AEs, including weight gain (2), hypertension (2), edema (1), fatigue (1), seizures (1) and for reasons not
stated (2). Proteinuria reduction ≥30 % was shown in 81.1 % (30/37) of patients and 62.2 % (23/37) showed
≥50 % proteinuria reduction. Proteinuria responses were greatest in MCD (n = 2/2 complete remission), MLN
(n = 2/2 partial remission), MPGN (n = 1/1 partial remission), FSGS (n = 12/15 [80.0 %] partial remission or
clinical response), and iMN (n = 8/11 [72.7 %] complete remission, partial remission, or clinical response).
Conclusions: Acthar gel may meet an important treatment need in patients with treatment-resistant NS in
response to first-line therapies, patients unable to tolerate first-line therapies, and in patients with advanced
disease.
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Background
Patients with nephrotic syndrome (NS) show a combin-
ation of clinical and laboratory features of renal diseases
characterized by heavy proteinuria, hypoalbuminemia,
and peripheral edema, with hyperlipidemia also frequently
seen. Effective treatment in patients who experience treat-
ment resistance or relapse following initial immunosup-
pressive treatment with steroids or cytotoxic drugs is an
ongoing challenge across NS etiologies [1–8]. There re-
mains a strong need for effective, tolerable treatments for
patients with treatment-resistant NS, particularly without
the renal and extra-renal toxicities associated with many
first- and second-line therapies [9]. One such treatment is
H.P. Acthar® Gel (adrenocorticotropic hormone, repository
corticotropin injection, Mallinckrodt ARD Inc., Hazelwood,
MO), FDA-approved in the US to induce diuresis or remis-
sion of proteinuria in NS without uremia of the idiopathic
type or that due to lupus erythematosus [10].
Adrenocorticotropic hormone (ACTH) treatment for
NS emerged in the US in the 1950s and was shown to be
effective for reduction or remission of proteinuria, de-
pending on the dose and duration of ACTH treatment
[11, 12]. However, by the late 1960s ACTH had largely
been replaced by steroids in NS treatment due to the con-
venience of oral dosing and the belief that they had similar
mechanisms of action and treatment effects [13]. Acthar
gel treatment for NS, the only FDA-approved ACTH
treatment in the US, has recently re-emerged [14–20].
Though current clinical data are limited, proteinuria
reduction resulting in complete or partial remission fol-
lowing Acthar gel treatment has been shown in patients
with idiopathic membranous nephropathy (iMN), idio-
pathic focal segmental glomerulosclerosis (FSGS), IgA
nephropathy (IgAN), minimal change disease (MCD),
and diabetic nephropathy (DN) [14–20]. Treatment regi-
mens of 80 U Acthar gel twice weekly for 6 months were
commonly used. One exception involved patients with
iMN who received either a 40 U or 80 U dose twice
weekly for either 3 months or 6 months, showing that
greater reduction in proteinuria was associated with
greater cumulative Acthar gel dose [19]. Additionally,
patients with advanced DN were treated with Acthar gel
16 U or 32 U daily for 6 months [17].
Our retrospective case series is the largest published to
date to examine the efficacy and safety of Acthar gel treat-
ment in patients with varied-etiology NS who have typically
failed multiple previous therapies. Proteinuria reduction as
well as frequency of adverse events (AEs) in patients treated
with Acthar gel within clinical practices were evaluated.
Methods
Patients
Patients eligible for inclusion were diagnosed with NS,
≥18 years old, received Acthar gel treatment for ≥6 months,
and had assessment of either 24-h proteinuria level (mg/d)
or urine protein:creatinine ratio (UPCR; g/g converted
to mg/d) prior to and following 6 months of Acthar gel
treatment. Patients did not have to meet a pre-specified
level of proteinuria at baseline to be included in the
study. NS etiologies within the patient cohort included
idiopathic NS due to FSGS, MN, IgAN, MCD, membra-
noproliferative glomerulonephritis (MPGN), fibrillary
glomerulonephritis (FGN), and 3 unbiopsied NS patients.
Additionally, patients with systemic lupus erythematosus
(SLE) class V membranous lupus nephritis (MLN), and
patients receiving off-label treatment for NS due to DN
were included. With the exception of the 3 unbiopsied
patients, all patients had biopsy-confirmed NS etiology.
The patient cohort represents all patients treated with
Acthar gel from the participating clinical practices who
met the specified inclusion criteria.
Ethics
This multicenter, retrospective case series of prescription-
based treatment with Acthar gel for NS included 6 US
clinical practices. The study received institutional review
board exemption from the New England Institutional
Review Board. All data reported in this paper have be
de-identified in order to protect patient confidentiality.
Data reviewed
Clinical records were reviewed for demographic and
clinical characteristics, including NS etiology, prior im-
munosuppressive or cytotoxic treatments, and levels of
proteinuria, serum albumin, and total cholesterol. Hypo-
albuminemia was defined as <3.5 g/dL. Renal function
was evaluated using serum creatinine (SCr) level and
renal insufficiency was defined as SCr >1.3 mg/dL. Acthar
gel treatment dosing regimen and concomitant medica-
tions, including angiotensin II receptor blockers (ARBs),
angiotensin-converting-enzyme inhibitors (ACEIs), and im-
munosuppressive and cytotoxic drugs, were documented.
Post-treatment proteinuria level and percentage re-
duction in proteinuria from baseline were examined.
Consistent with prior studies, complete remission was
defined as final proteinuria <500 mg/d, and partial re-
mission was defined as ≥50 % reduction in proteinuria
from baseline and final proteinuria 500–3500 mg/d,
with examination of preserved or improved renal func-
tion as indicated by SCr that does not worsen >25 %
from baseline [14–16]. Clinical response was defined as
≥30 % reduction in proteinuria from baseline that did
not meet criteria for complete or partial remission.
Inclusion of the clinical response outcome aligns with
the treatment suggestion for calcineurin inhibitors
(CNIs) in patients with iMN, stating therapy should be
continued in patients showing an initial substantial pro-
teinuria reduction of 30–50 % at 4–6 months treatment
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because the optimal treatment duration with calcine-
urin inhibitors is unknown and the patient’s response
suggests possible further proteinuria improvement with
continued therapy [2]. The clinical response definition
is also consistent with the clinical practice of the
current study’s treating nephrologists when determin-
ing the duration of a trial of treatment in patients. That
is, treatment is extended following a ≥30 % reduction
in proteinuria because this degree of improvement has
been experienced as a clinically meaningful change for
patients. Patients showing no response failed to meet
remission or clinical response criteria.
The frequency of AEs and the frequency of early dis-
continuation of treatment due to AEs were documented.
Patients with an early termination of treatment without
a stated reason were included in the count of early
termination due to AEs.
Data analysis
Categorical variables were summarized using counts and
percentages. Descriptive statistics summarized continuous
variables. Paired t-tests examined change from baseline to
post-Acthar gel therapy in proteinuria level, serum albu-
min, and total cholesterol. Between-group t-tests were
used to compare percent reduction in proteinuria in pa-
tients who showed renal insufficiency at baseline versus
patients who did not show renal insufficiency. Statistical




Characteristics of patients by NS etiology group are pre-
sented in Table 1. Cases included 44 patients across NS
etiologies FSGS (n = 15), iMN (n = 11), IgAN (n = 5), DN
(n = 4), MLN (n = 2), MCD (n = 2), MPGN (n = 1), FGN,
(n = 1), and 3 unbiopsied NS patients. The majority
(30/44; 68.2 %) had failed ≥1 prior immunosuppressive
or cytotoxic therapy, and 20 of 44 (45.5 %) had failed
≥2 prior immunosuppressive and/or cytotoxic treat-
ments. All patients received Acthar gel 80 U twice
weekly, with the exception of 1 patient with iMN who
received 40 U twice weekly. Continuing treatment with
standard care ARB and/or ACEI maximum blockade
was received by 36/44 (81.8 %) patients (Tables 2, 3, 4
and 5; 12/15 FSGS, 9/11 iMN, 5/5 IgAN, 4/4 DN, 2/2
MLN, 2/2 MCD, 1/1 MPGN, 0/1 FGN, 1/3 unbiopsied
NS) and dosing was maintained throughout the Acthar
gel treatment period unless the patient required dose
modification due to AEs.
Total group treatment response
There was significant proteinuria reduction from base-
line to post-Acthar gel treatment (n = 40; mean reduc-
tion 3984.8 ± 4069.1 mg/d, P < 0.0001). Total cholesterol
showed significant decline from baseline to post-Acthar
gel therapy (n = 21; mean reduction 38.3 ± 58.8 mg/dL,
P = 0.007). Mean serum albumin at baseline indicated hy-
poalbuminemia (n = 40, 3.0 ± 0.8 g/dL; range 1.4–4.0 g/dL),
and significant improvement was shown post-Acthar gel
therapy (n = 35; mean improvement 0.53 ± 0.6 g/dL,
P < 0.0001).
Acthar gel treatment was completed by 37 patients,
and 7 (15.9 %) patients had early termination of treat-
ment due to AEs. Among the 37 treatment completers,
81.1 % (30/37) showed ≥30 % proteinuria reduction, and
62.2 % (23/37) showed ≥50 % proteinuria reduction.
Proteinuria remission was shown by 56.8 % (21/37) of
patients, either complete (n = 4, 10.8 %) or partial (n =
17, 45.9 %) remission. Inclusion of clinical response
patients (n = 9) resulted in 81.1 % (30/37) of patients
showing substantial proteinuria reduction. Of these
patients, 80 % (24/30) had failed ≥1 and 53.3 % (16/30)
Table 1 Demographic and clinical characteristics of NS patients (N = 44) treated with Acthar gel
NS etiology Age ± SD, years Gender, n (%) female Race/ethnicity, n (%) White Previous IST/CT, n (%) yes
FSGS (n = 15) 53.3 ± 12.9 7 (47) 12 (80) 12 (80)
iMN (n = 11) 53.6 ± 18.9 4 (36) 10 (91) 10 (91)
IgAN (n = 5) 35.0 ± 8.4 2 (40) 4 (80) 1 (20)
DN (n = 4) 54.0 ± 19.9 2 (50) 4 (100) 0
MLN (n = 2) 37.5 ± 4.9 1 (50) 0 2 (100)
MCD (n = 2) 33.5 ± 13.4 2 (100) 2 (100) 2 (100)
FGN (n = 1) 63.0 0 1 (100) 1 (100)
MPGN (n = 1) 22.0 1 (100) 1 (100) 0
Othera (n = 3) 55.7 ± 6.1 2 (67) 2 (67) 2 (67)
Abbreviations: CT cytotoxic therapy, DN diabetic nephropathy, FGN fibrillary glomerulonephritis, FSGS idiopathic focal segmental glomerulosclerosis, IgAN IgA
nephropathy, iMN idiopathic membranous nephropathy, IST immunosuppressive therapy, MCD minimal change disease, MLN membranous lupus nephritis
(class V), MPGN membranoproliferative glomerulonephritis, NS nephrotic syndrome
a“Other” includes 3 patients with unbiopsied NS
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Table 2 Proteinuria reduction and treatment response in patients with FSGS treated with Acthar gel





















Tacrolimus, MMF 3.0 0.9 5800 Partial remission
3.4 0.8 2016
−11.1 −65.2
3 Prednisone None 3.2 2.2 5000 Clinical response
3.8 2.2 3422
0 −31.6
4 None ARB 3.9 4.8 7900 Partial remission
4.0 6.7 2300
39.6 −70.9
5 None ARB 3.2 3.2 3840 Early termination
NA NA NA
NA NA
6 Prednisone, cyclosporine ARB, ACEI cyclosporine 2.8 3.0 7500 Partial remission
3.9 2.5 1768
−16.7 −76.4
7 Prednisone, cyclosporine ARB, ACEI cyclosporine 3.1 1.1 5280 Clinical response
3.6 1.3 3560
18.2 −32.6
8 None ACEI NA 1.2 4000 Partial remission
NA 1.1 765
−8.3 −80.9
9 Prednisolone, methotrexate ACEI, prednisolone 3.1 1.6 9306 Partial remission
3.3 2.0 2773
25.0 −70.2
10 MMF ACEI, MMF NA 4.4 2830 Clinical response
4.0 5.0 1629
13.6 −42.4
11 Prednisone ARB 3.5 2.4 3500 Partial remission
3.7 3.1 750
29.2 −78.6




13 Prednisone, cyclosporine None 3.2 3.1 3250 Clinical response
3.5 4.1 2073
32.3 −36.2
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had failed ≥2 prior immunosuppressive or cytotoxic
therapies.
Among the 44 patients, 26 (59.1 %) showed SCr >1.3 mg/
dL at baseline. There was a greater mean percent pro-
teinuria reduction in patients with SCr ≤1.3 mg/dL
(n = 14; 72.2 ± 26.9 % reduction) compared with pa-
tients showing SCr >1.3 mg/dL (n = 22; 41.0 ± 29.7 % re-
duction, P = 0.0031). Similarly, among patients showing
complete or partial remission or clinical response, greater
mean percent proteinuria reduction occurred in patients
without renal function impairment (n = 13; 77.5 ± 19.0 %
reduction) compared with SCr >1.3 mg/dL (n = 16; 55.6 ±
16.9 % reduction, P = 0.0029).
Treatment response by NS etiology
The percentage of patients showing complete remission,
partial remission, or clinical response to Acthar gel treat-
ment varied across NS etiologies (Fig. 1). The highest
proteinuria responses were seen in patients with MCD
(n = 2/2 complete remission), MLN (n = 2/2 partial remis-
sion), MPGN (n = 1/1 partial remission), FSGS (n = 12/15
[80.0 %] partial remission or clinical response), and iMN
(n = 8/11 [72.7 %] complete or partial remission or clinical
response). Lower proteinuria responses were seen in pa-
tients with IgAN (n = 2/5 [40.0 %] partial remission or
clinical response) and DN (n = 1/4 [25 %] clinical re-
sponse). The single patient with FGN showed no response.
Within the “Other” category of unbiopsied NS patients, 1
patient showed partial remission and 1 patient showed
clinical response.
FSGS
Following Acthar gel, 86.7 % (13/15) of patients showed
≥30 % proteinuria reduction and 60 % (9/15) showed
≥50 % proteinuria reduction (Table 2). There was sig-
nificant proteinuria reduction from baseline to post-
Acthar gel treatment (n = 14; mean reduction 3021.7 ±
1970.6 mg/d, P < 0.0001). No patient showed complete
remission; however, 9 (60 %) showed partial remission,
and 4 (26.7 %) showed clinical responses ranging from
31.6–42.4 % proteinuria reduction. One patient showed
no response, and 2 patients had early termination. The
early termination for 1 patient was due to increased
swelling; no reason was provided for the second pa-
tient, who achieved partial remission prior to termin-
ation of treatment. Renal insufficiency at baseline due
to SCr >1.3 mg/dL was shown in 12/15 (80 %) patients.
Among the Acthar gel treatment responders, worsening
SCr >25 % was shown in 2 patients with partial remission
and 1 patient with clinical response and all 3 patients
had SCr >1.3 at baseline (Table 2). Total cholesterol
significantly declined from baseline (n = 8; mean reduc-
tion 32.5 ± 28.9 mg/dL, P < 0.02), and serum albumin
significantly increased (n = 11; mean increase 0.39 ±
0.4 g/dL, P = 0.009). Hypoalbuminemia was shown by
8/15 patients (53.3 %) at baseline (range 1.7–3.2 g/dL),
and improved in 7 of these patients by post-treatment
(range 2.7–3.9 g/dL).
iMN
Proteinuria reduction ≥50 % occurred in 72.7 % (8/11)
of patients with iMN (Table 3). There was significant
proteinuria reduction from baseline to post-Acthar gel
treatment (n = 10; mean reduction 4245.5 ± 4085.5 mg/d,
P = 0.009). Two patients (18.2 %) showed complete remis-
sion, 4 (36.4 %) showed partial remission, and 2 (18.2 %)
showed clinical responses ranging from 51.5–60.0 % pro-
teinuria reduction. Two patients showed no response (1
patient was diagnosed with iMN and FSGS), and 1 patient
had early termination due to an AE involving fatigue. SCr
>1.3 mg/dL was found in 5/11 patients (45.5 %) at base-
line. The mean reduction in total cholesterol (n = 5; 9.4 ±
10.2 mg/dL) and increase in serum albumin (n = 9; 0.52 ±
0.7 g/dL) were not significant (P > 0.06). Hypoalbumin-
emia was shown by 6/11 patients (54.5 %) at baseline
(range 1.4–3.3 g/dL), and 5 of these patients showed im-
provement post-treatment (range 2.1–3.4 g/dL).
IgAN
Proteinuria reduction ≥30 % occurred in 60 % (3/5) of
patients and 40 % (2/5) showed ≥50 % proteinuria re-
duction (Table 4). The mean proteinuria reduction (n = 4)
Table 2 Proteinuria reduction and treatment response in patients with FSGS treated with Acthar gel (Continued)





ACEI 3.6 1.4 4070 No response
3.3 1.5 3930
7.1 −3.4
Abbreviations: ACEI angiotensin-converting-enzyme inhibitor, ARB angiotensin II receptor blockers, CT cytotoxic therapy, FSGS idiopathic focal segmental
glomerulosclerosis, IST immunosuppressive therapy, MMF mycophenolate mofetil, NA not available
aPost-Acthar gel assessment occurred following 4 months of treatment
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was 2917.0 ± 4225.4 mg/d. Two patients showed partial
remission and 1 patient showed clinical response (36.4 %
proteinuria reduction). One patient showed no response
and 2 patients had early termination. Early termination
for 1 patient was due to AEs of weight gain and hyper-
tension, and for 1 patient was stated as a patient deci-
sion. This latter patient showed partial remission, with
92 % proteinuria reduction before treatment termin-
ation. SCr >1.3 mg/dL occurred in 2/5 patients (40 %)
at baseline. Total cholesterol and serum albumin were
available for 2 patients. Total cholesterol decreased
from 250 mg/dL to 230 mg/dL and serum albumin in-
creased from 3.0 g/dL to 4.0 g/dL in 1 patient whereas
the second patient had increased total cholesterol from
Table 3 Proteinuria reduction and treatment response in patients with iMN treated with Acthar gel














1 Prednisone, cyclophosphamide, rituximab ARB, ACEI 2.7 1.3 13,600 Clinical response
3.2 1.3 6600
0 −51.5
2 Prednisone, IVMP Prednisone 1.4 1.2 6354 Partial remission
3.3 1.1 1000
−8.3 −84.3
3 None None 1.5 2.5 15,400 Partial remission
3.1 1.9 2376
−24.0 −84.6
4 Prednisone, cyclosporine ACE 1.6 1.9 10,000 Clinical response
2.1 1.9 4000
0 −60.0
5 Prednisone ARB, ACEI 3.8 1.9 4000 No response
3.7 2.0 3475
5.3 −13.1
6 Tacrolimus ACEI 3.3 1.0 5500 Complete remission
3.4 0.9 349
−10.0 −93.7
7 Prednisone, tacrolimus, chlorambucil ARB 3.9 0.9 2400 Complete remission
Tacrolimus 4.0 1.0 163
−11.1 −93.2
8 Prednisone, cyclosporine ACEI 3.2 1.3 3070 Early termination
NA NA NA
NA NA
9 Prednisone, cyclosporine ACEI 3.8 2.1 1930 Partial remission
3.7 2.2 728
4.8 −62.3
10 Prednisone, tacrolimus, cyclophosphamide ARB 3.5 1.3 5210 Partial remission
3.7 1.6 1780
23.1 −65.8
11 Prednisone, IVMP, cyclophosphamide ACEI NA 3.3 5132 No response
NA 3.8 6600
15.2 28.6
Abbreviations: ACEI angiotensin-converting-enzyme inhibitor, ARB angiotensin II receptor blockers, CT cytotoxic therapy, iMN idiopathic membranous nephropathy,
IST immunosuppressive therapy, IVMP intravenous methylprednisolone, NA not available
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161 mg/dL to 242 mg/dL and decreased serum albumin
from 4.0 g/dL to 3.6 g/dL. One patient showed hypoal-
buminemia at baseline (3.0 g/dL) and improved post-
treatment (4.0 g/dL).
DN
Among 4 patients, 1 (25 %) showed ≥30 % proteinuria
reduction (37.3 %, Table 4). The mean proteinuria reduc-
tion (n = 4) was 1797.3 ± 2267.3 mg/d. Two patients had
no response to treatment, including 1 patient with DN
and FSGS who progressed to renal replacement therapy.
One patient had early termination due to AEs involving
weight gain and hypertension. All 4 patients showed SCr
>1.3 mg/dL. There was a mean reduction in total choles-
terol (n = 2; 104.5 ± 13.4 mg/dL) and in serum albumin
(n = 4; 0.05 ± 0.2 g/dL). Hypoalbuminemia was shown by
all 4 patients at baseline (range 2.0–3.4 g/dL) and im-
proved to 3.5 g/dL in 1 patient.
Table 4 Proteinuria reduction and treatment response in patients with IgA nephropathy/diabetic nephropathy treated with Acthar
gel
Patient Previous IST/CT Concurrent
medications











1 None ARB, ACEI 3.9 2.8 4000 Early termination
NA NA NA
NA NA
2 None ARB, ACEI 3.9 1.4 2674 Clinical response
NA 1.5 1700
7.1 −36.4
3 None ARB 4.0 1.3 2439 No response
3.6 1.3 2360
0 −3.2










1 None ACEI 2.0 1.9 25000 No response
2.0 4.9 23000
157.9 −8.0
2 None ARB, ACEI 3.3 3.4 14000 Early termination
3.3 4.4 11600a
29.4 −17.1
3 None ACEI 3.1 4.8 17570 No response
2.8 5.7 18886
18.8 7.5
4 None ACEI 3.4 2.5 11000 Clinical response
3.5 2.5 6895
0 −37.3
Abbreviations: ACEI angiotensin-converting-enzyme inhibitor, ARB angiotensin II receptor blockers, CT cytotoxic therapy, DN diabetic nephropathy, IgAN IgA
nephropathy, IST immunosuppressive therapy, MMF mycophenolate mofetil, NA not available
aPost-Acthar gel assessment occurred following 3 months of treatment
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MLN
Both patients with MLN showed ≥50 % proteinuria re-
duction (86.4 % and 87.7 %), and showed partial remis-
sion (Table 5). The mean proteinuria reduction (n = 2)
was 12173.5 ± 7442.3 mg/d. The patients did not ex-
perience renal insufficiency, but they did show hypoal-
buminemia at baseline (1.7 and 1.8 g/dL), which
improved post-treatment (3.3 and 2.4 g/dL). There was
a mean increase in serum albumin (n = 2; 1.10 ± 0.6 g/dL).
Change in total cholesterol was not available for either
patient.
MCD
Both patients with MCD showed ≥50 % proteinuria re-
duction (88 % and 99.4 %), and showed complete remis-
sion (Table 5). The mean proteinuria reduction (n = 2)
was 8335.0 ± 9299.9 mg/d. Renal insufficiency was not
present but 1 patient showed a worsening of SCr from
Table 5 Proteinuria reduction and treatment response in patients treated with Acthar gel, by etiologic diagnosis
Patient Previous IST/CT Concurrent
medications











1 Prednisone, cyclophosphamide ACEI, prednisone 1.8 1.0 8000 Partial remission
3.3 0.8 1089
−20.0 −86.4




1 Prednisone ACEI 3.7 0.9 2000 Complete remission
4.7 1.2 241
33.0 −88.0
2 Prednisone, cyclosporine ACEI 2.1 1.0 15000 Complete remission
2.3 0.7 89
−30.0 −99.4
FGN Prednisone, MMF, rituximab MMF 1.4 5.6 13000 No response
3.4 9.0 10000
60.7 −23.1




1 UNS Prednisone None 3.5 1.6 3000 Clinical response
4.6 2.2 1600
37.5 −46.7
2 UNS Prednisone ACEI 3.5 1.7 4500 Partial remission
4.0 1.9 2000
11.8 −55.6
3 UNS None None 3.1 1.3 5500 Early termination
3.3 1.3 NA
0 NA
Abbreviations: ACEI angiotensin-converting-enzyme inhibitor, ARB angiotensin II receptor blockers, FGN fibrillary glomerulonephritis, MCD minimal change disease,
MLN membranous lupus nephritis (class V), MPGN membranoproliferative glomerulonephritis, NA not available, UNS unbiopsied nephrotic syndrome
a“Other” includes 3 patients with unbiopsied NS
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0.9 at baseline to 1.2 mg/dL (33 %). One patient showed
hypoalbuminemia at baseline (2.1 g/dL) with minimal
improvement post-treatment (2.3 g/dL). There was mean
total cholesterol reduction (n = 2; 81.5 ± 2.1 mg/dL) and
mean serum albumin increase (n = 2; 0.60 ± 0.6 g/dL).
FGN
The patient with FGN showed no response to treatment
(Table 5). The patient had advanced disease that required
renal replacement therapy, and dialysis was initiated be-
fore starting Acthar gel therapy.
MPGN
The patient with MPGN showed partial remission, with
78.6 % proteinuria reduction (Table 5). This patient did
not show renal insufficiency but did show hypoalbumin-
emia at baseline (1.5 g/dL) that improved post-treatment
(3.3 g/dL). Total cholesterol was reduced from 360 mg/dL
to 180.0 mg/dL.
Unbiopsied NS
Among the 3 patients with unbiopsied NS, 1 patient
showed partial remission (55.6 % proteinuria reduction),
and 1 patient showed clinical response (46.7 % protein-
uria reduction) (Table 5). The third patient had early ter-
mination of treatment due to an AE involving seizures.
The patients with partial remission and clinical response
showed renal insufficiency at baseline and the patient
with a clinical response showed worsening of SCr >25 %.
Hypoalbuminemia was present in the patient with early
termination. The patient with partial remission had a total
cholesterol reduction of 100 mg/dL.
Safety and tolerability
AEs during Acthar gel treatment were reported by
29.5 % (13/44) of patients and included increased swelling,
weight gain, hypertension, hyperglycemia, fatigue, dizzi-
ness, hypokalemia, upper respiratory infection, seizures,
and decreased bone mineralization (Table 6). Early ter-
mination due to treatment-related AEs occurred in 15.9 %
(7/44) of patients. Among these 7 patients, 1 patient with
IgAN terminated treatment early by “patient decision”
and 1 patient with FSGS terminated treatment early with-
out a specific reason provided. Both patients showed par-
tial remission before early termination (Table 2, Table 4).
Discussion
This retrospective case series is the largest published to
date to examine the efficacy and safety of Acthar gel in
the treatment of patients with NS of varying etiologies,
68.2 % of whom had received prior NS treatment with
immunosuppressive or cytotoxic therapies, who were
receiving clinic-based prescription treatment. A signifi-
cant proteinuria reduction was shown, and approxi-
mately 80 % of patients who completed Acthar gel
treatment showed a substantial proteinuria reduction of
≥30 %, including patients who met criteria for complete
remission, partial remission, or clinical response. Most
patients tolerated Acthar gel therapy well. The AEs
were consistent with prior studies of Acthar gel in
patients with NS, in which AEs were typically steroid-
like, with most being mild to moderate in severity
and transient [14–17].
The relative rarity of NS etiologies has contributed
to the scarcity of large-scale, prospective, randomized,
Fig. 1 Treatment response in patients with NS treated with Acthar gel, by etiologic diagnosis. “Other” includes 3 patients with unbiopsied NS.
Abbreviations: DN, diabetic nephropathy; FGN, fibrillary glomerulonephritis; FSGS, idiopathic focal segmental glomerulosclerosis; IgAN, IgA
nephropathy; iMN, idiopathic membranous nephropathy; MCD, minimal change disease; MLN, membranous lupus nephritis (class V); MPGN,
membranoproliferative glomerulonephritis
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controlled trials on which to base treatment recom-
mendations [1]. As a result, the majority (67 %) of
the recommendations provided by the comprehensive
Kidney Disease: Improving Global Outcomes (KDIGO)
2012 Clinical Practice Guideline for Glomerulonephritis
were graded as a suggestion rather than recommendation
and with an evidence quality rating of C or D, indicating
low to very low quality of evidence [1]. Evaluation of add-
itional treatment options is urgently needed for patients
with FSGS, iMN, IgAN, MCD, and MLN who are not
responsive to the first-line treatments—typically cortico-
steroids, cyclophosphamide, CNIs, and mycophenolate
mofetil (MMF)—or who are unable to tolerate the first-
line treatments. For example, approximately 25 % of pa-
tients with MCD have been shown to be steroid-resistant
and approximately 30 % of initial steroid responders show
frequent relapses, and approximately one-third of MLN
patients have been shown not to respond to the current
American College of Rheumatology (ACR)-recommended
initial treatment with prednisone plus MMF [4, 7, 8].
While acknowledging retrospective case series study de-
sign limitations, the current large case series provides
much-needed Acthar gel treatment response information
in diverse patients, including patients with advanced
disease and treatment-resistant NS. Half (53.3 %) of the
patients who showed proteinuria response to Acthar gel
had failed ≥2 prior immunosuppressive or cytotoxic ther-
apies, and approximately half had impaired renal function.
Among all patients and among patients who showed pro-
teinuria reduction, patients with preserved renal function
showed greater percent proteinuria reduction following
Acthar gel treatment, indicating earlier treatment with
Acthar gel may be especially beneficial.
Importantly, studies of patients with FSGS, iMN, and
IgAN have indicated that partial remission and improved
disease control are associated with better renal outcomes,
even if patients relapse again [6, 21, 22]. Although
complete remission is the ideal outcome, these studies
suggest reduced proteinuria that does not meet complete
remission criteria provides a meaningful treatment benefit
compared with no improved disease control [6, 21, 22].
The optimal treatment duration for Acthar gel in patients
with NS of varied etiology is not yet known. Our inclusion
of the clinical response outcome identifying patients with
substantial proteinuria reduction ≥30 % is consistent with
the suggestion that longer-duration treatment beyond
6 months is indicated in iMN patients receiving CNIs who
show proteinuria reduction of 30–50 %, with the goal of
achieving partial or complete remission with longer-
duration therapy [2]. Additionally, within the clinic, our






Treatment-related AEs Early termination due to AEsa, n (%)
FSGS (n = 15) 3 (20 %) Increased swelling (n = 1)
Hyperglycemia (n = 2)
Hypertension (n = 1)
Weight gain (n = 1)
Upper respiratory infections (n = 1)
1 (6.7 %) Edema
1 (6.7 %) Reason not given
iMN (n = 11) 4 (36.4 %) Fatigue (n = 1)
Dizziness (n = 1)
Weight gain (n = 2)
Hypokalemia (n = 1)
1 (9 %) Fatigue
IgAN (n = 5) 1 (20 %) Weight gain (n = 1)
Hypertension (n = 1)
1 (20 %) Weight gain, hypertension
1 (20 %) Patient decision
DN (n = 4) 3 (75 %) Weight gain (n = 2)
Hypertension (n = 1)
Hyperglycemia (n = 1)
Decreased bone mineralization (n = 1)
1 (25 %) Weight gain, hypertension
MLN (n = 2) 0 0
MCD (n = 2) 0 0
FGN (n = 1) 0 0
MPGN (n = 1) 0 0
Otherb (n = 3) 2 (66.7 %) Seizures (n = 1)
Hyperglycemia (n = 1)
Weight gain (n = 1)
Hypertension (n = 1)
1 (33.3 %) Seizures
Abbreviations: AEs adverse events, DN diabetic nephropathy, FGN fibrillary glomerulonephritis, FSGS idiopathic focal segmental glomerulosclerosis, IgAN IgA
nephropathy, iMN idiopathic membranous nephropathy, MCD minimal change disease, MLN membranous lupus nephritis (SLE class V), MPGN membranoproliferative
glomerulonephritis, UNS unbiopsied nephrotic syndrome
aPatients without a specific reason given for early termination of treatment were included in the count of early termination due to AEs
b“Other” includes 3 patients with unbiopsied NS
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experience with patients who show proteinuria reduction
≥30 % is clinically meaningful improvement in the patient’s
report of feeling better. Longer-term treatment follow-up
of these patients is needed to determine whether the pro-
teinuria reduction is maintained, improves to remission or
deteriorates to relapse.
In the two largest NS etiology patient groups, FSGS
and iMN, the majority of patients showed proteinuria
reduction ≥50 % following Acthar gel treatment, and the
proteinuria reduction was significant. More than half of
patients with FSGS showed partial remission and another
quarter showed clinical response. Partial remission is a
meaningful improvement for these patients, as significant
improvement in kidney survival has been associated with
partial remission of FSGS [14–16, 21]. Among patients
with iMN, more than two-thirds of patients showed either
complete or partial remission or clinical response to
Acthar gel therapy. It has been stated that the recom-
mended first-line therapy for patients with iMN, alkylating
agents, should be restricted to patients who show a high
risk of disease progression due to the toxicity associated
with the agents [23]. Additionally, it has been shown that
approximately 50 % of patients with iMN with persistent
high-grade proteinuria will progress to end-stage renal
disease (ESRD) [1]. The current case series findings,
outcomes from previous studies examining Acthar gel
in patients with iMN, and the finding that risk of pro-
gression is significantly reduced with at least partial
remission suggest that Acthar gel may provide an im-
portant treatment option for patients with treatment-
resistant iMN [14, 15, 19, 22].
The remaining NS etiology patient groups each had ≤5
patients, limiting conclusions about potential Acthar gel
treatment efficacy. Proteinuria reduction to partial or
complete remission was encouraging in patients with
MCD or MLN and further study of Acthar gel therapy is
warranted in these NS etiologies. Similarly, proteinuria
response to Acthar gel therapy in 3 of the 5 patients
with IgAN in our case series was consistent with prior
single-case and small case series studies showing sub-
stantial proteinuria reduction [14, 15]. Compared with
the 4 patients with DN in our case series, a stronger
proteinuria response to Acthar gel therapy has been
demonstrated in patients with DN using a treatment
regimen of 16 U or 32 U daily for 6 months [17].
Potential mechanisms of action of Acthar gel include
steroid-independent effects through the melanocortin
system and steroid-related effects [13, 24, 25]. Acthar
gel in an animal model of progressive renal tubulointer-
stitial injury showed suppression of tubulointerstitial
inflammation, tubular atrophy, and fibrosis through
anti-inflammatory effects mediated by melanocortin re-
ceptor 1 (MC1R) on tubular epithelial cells [26]. MC1Rs
have been shown in podocytes, glomerular endothelial
cells, and mesangial cells, and an MC1R agonist re-
sulted in significantly reduced proteinuria in the passive
Heymann nephritis animal model [24]. Thus, Acthar
gel steroid-independent effects may occur through
melanocortin receptors, and more specifically MC1R,
which may provide an explanation for the efficacy of
Acthar gel in treatment-resistant and steroid-resistant
patients [24, 26]. Additionally, the cumulative dose of
Acthar gel, through the dosing regimen and treatment
duration, may be an important factor. Among iMN pa-
tients, those receiving a greater cumulative dose of
Acthar gel (2800 U) showed greater proteinuria reduc-
tion compared with lower cumulative doses (880 U and
1760 U) [19].
The current report is the largest case series to date to
examine Acthar gel treatment of patients in real-world,
clinical nephrology practices with an all-inclusive patient
population. Strengths include the large patient sample
with diverse NS etiologies and the inclusion of a major-
ity of patients with prior NS treatment and with im-
paired renal function. The real-world clinical practice of
Acthar gel treatment in patients with NS helps to eluci-
date the AEs that may be expected. Limitations include
the small patient numbers in several of the NS etiolo-
gies, the retrospective design without a control group,
and the possibility that concurrent therapy or long-term
effects of prior immunosuppressive or cytotoxic therapy
may have contributed to the proteinuria response during
Acthar gel therapy in some patients. Patients in the
current study were primarily White, which may limit the
applicability of study findings in more racially diverse
populations. Initiation of anti-proteinuria treatment was
based on the treating clinician’s judgment within the clin-
ical management of their patient’s changing NS symp-
toms. As a result, excluding patients with IgAN, 8 patients
began treatment at a non-nephrotic proteinuria level
<3500 mg/d. Proteinuria was used as a surrogate endpoint
and the possible long-term benefit of Acthar gel in pre-
venting ESRD was not examined. Additionally, longer
treatment duration and follow-up may be needed for
optimal treatment responses. The relapse rate following
successful treatment with Acthar gel and possible use of
other therapies post-Acthar gel treatment cessation are
not yet known.
Conclusion
The current case series findings support a potential
short-term benefit of Acthar gel therapy in patients with
NS, particularly FSGS and iMN etiologies, and indicate
Acthar gel treatment is well tolerated. Among the pa-
tients who completed ≥6 months of treatment, 80 %
showed ≥30 % proteinuria reduction, and almost two-
thirds showed ≥50 % proteinuria reduction. The majority
of patients who showed proteinuria reduction had failed
Madan et al. BMC Nephrology  (2016) 17:37 Page 11 of 13
prior immunosuppressive and cytotoxic therapies, and
approximately half showed impaired renal function prior
to Acthar gel treatment. These findings indicate that
Acthar gel may meet an important treatment need in
patients with NS that is treatment-resistant in response
to first-line therapies or who are unable to tolerate first-
line therapies and in patients with advanced disease.
Future research is needed to determine whether patients
who show a proteinuria clinical response without re-
mission benefit from longer-term treatment and show
continued clinical improvement. Further research using
prospective, controlled trials with longer-duration treat-
ment and follow-up assessments to examine different
Acthar gel regimens and cumulative dose effects in
varied-etiology NS is warranted.
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